Capstone Holding (CAPS)
NASDAQ:CAPS
Top Page
Capstone Holding
(NASDAQ:CAPS)
Select Model
Select Model
Rating:41Neutral
Price Target:
$0.57
▼(-19.30% Downside)
Action:DowngradedDate:01/28/26
The score is primarily held down by weak financial performance (ongoing losses and renewed cash burn), with bearish technicals reinforcing downside pressure. Corporate updates provide some offset via growth/monetization actions and reduced near-term costs, but listing-compliance risk and loss-based valuation keep the overall score low.
Positive Factors
Acquisition-driven revenue scale
Successful recent acquisitions have materially increased scale and revenue run-rate, creating a broader revenue base and more predictable cash flows. Growing scale improves bargaining power with suppliers and enhances ability to absorb fixed costs, supporting more durable margin expansion and strategic optionality.
Negative Factors
Persistent cash burn
The company has returned to negative operating and free cash flow, reversing prior positive FCF trends. Continued cash burn undermines funding autonomy, increases refinancing or equity issuance risk, and can force asset sales or curtailed investment if operational improvements don't restore consistent cash generation.
Read all positive and negative factors
Positive Factors
Negative Factors
Acquisition-driven revenue scale
Successful recent acquisitions have materially increased scale and revenue run-rate, creating a broader revenue base and more predictable cash flows. Growing scale improves bargaining power with suppliers and enhances ability to absorb fixed costs, supporting more durable margin expansion and strategic optionality.
Read all positive factors
Capstone Holding (CAPS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$4.92M
Dividend YieldN/A
Average Volume (3M)1.37M
Price to Earnings (P/E)―
Beta (1Y)1.13
Revenue Growth1.52%
EPS Growth77.22%
CountryUS
Employees36
SectorBasic Materials
Sector Strength58
IndustryConstruction Materials
Share Statistics
EPS (TTM)N/A
Shares Outstanding9,087,873
10 Day Avg. Volume1,309,522
30 Day Avg. Volume1,370,765
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)-0.12
Price to Sales (P/S)0.00787
P/FCF Ratio0.10
Enterprise Value/Market Cap5.18
Enterprise Value/Revenue0.57
Enterprise Value/Gross Profit2.60
Enterprise Value/Ebitda-8.90
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Capstone Holding Business Overview & Revenue Model
Company Description
Capstone Therapeutics Corp., a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs tha...
How the Company Makes Money
Capstone Therapeutics generates revenue through multiple streams, primarily from the development and commercialization of its therapeutic products. The company may receive funding from strategic partnerships with larger pharmaceutical companies, i...
Capstone Holding Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
41
Neutral
Cash Flow
28
Negative
| Breakdown | TTM | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 44.72M | 44.88M | 48.35M | 61.56M | 66.74M | 45.45M |
| Gross Profit | 9.78M | 9.57M | 9.61M | 16.53M | 16.32M | 10.94M |
| EBITDA | -2.86M | -121.00K | -1.75M | 4.23M | 5.02M | 2.64M |
| Net Income | -5.54M | -2.56M | -3.82M | 2.31M | 3.92M | 10.46M |
Balance Sheet | ||||||
| Total Assets | 58.48M | 47.22M | 52.70M | 65.21M | 60.85M | 54.87M |
| Cash, Cash Equivalents and Short-Term Investments | 730.00K | 11.00K | 52.00K | 23.00K | 50.00K | 0.00 |
| Total Debt | 23.25M | 16.61M | 20.33M | 28.80M | 28.34M | 20.81M |
| Total Liabilities | 31.33M | 50.28M | 50.26M | 57.04M | 31.78M | 25.77M |
| Stockholders Equity | 27.16M | -3.06M | 2.44M | 8.17M | 29.08M | 29.11M |
Cash Flow | ||||||
| Free Cash Flow | -1.18M | 3.70M | 1.24M | -3.06M | 2.55M | 639.00K |
| Operating Cash Flow | -1.15M | 3.82M | 1.45M | -2.89M | 3.72M | 642.00K |
| Investing Cash Flow | -2.46M | -120.00K | -208.00K | -173.00K | -931.00K | -3.00K |
| Financing Cash Flow | 4.32M | -3.74M | -1.21M | 3.04M | -2.74M | -697.00K |
Capstone Holding Technical Analysis
Negative
0.71
Price Trends
0.63
Negative
0.71
Negative
1.02
Negative
Market Momentum
-0.02
Positive
39.94
Neutral
18.30
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CAPS, the sentiment is Negative. The current price of 0.71 is above the 20-day moving average (MA) of 0.67, above the 50-day MA of 0.63, and below the 200-day MA of 1.02, indicating a bearish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 39.94 is Neutral, neither overbought nor oversold. The STOCH value of 18.30 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CAPS.
Capstone Holding Risk Analysis
Capstone Holding disclosed 18 risk factors in its most recent earnings report. Capstone Holding reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Capstone Holding Peers Comparison
UnderperformOutperform
Sector (61)
CAPS
Capstone Holding
0.54
-1.98
-78.53%
RETO
ReTo Eco-Solutions
0.80
-17.60
-95.66%
FEAM
5E Advanced Materials, Inc.
1.64
-2.04
-55.43%
STAI
ScanTech AI Systems
0.15
-36.85
-99.59%
Capstone Holding Corporate Events
Business Operations and StrategyStock BuybackFinancial DisclosuresPrivate Placements and FinancingRegulatory Filings and ComplianceStock Split
Capstone Holding Highlights Monetization Strategy and Capital Priorities
Positive
Jan 28, 2026
On January 28, 2026, Capstone Holding Corp. published an investor FAQ outlining how it is shifting from pure platform expansion to monetizing scale in the building products sector, emphasizing its technology and AI-enabled tools as core drivers of...
Business Operations and StrategyExecutive/Board ChangesFinancial Disclosures
Capstone Holding Enters Fee Waiver Agreement to Ease 2026 Costs
Positive
Jan 27, 2026
On January 21, 2026, TotalStone, LLC, the operating company of Capstone Holding Corp., entered into a conditional fee waiver and deferral agreement under which related party Brookstone Partners IAC agreed to waive $400,000 of 2026 management and c...
Delistings and Listing ChangesRegulatory Filings and Compliance
Capstone Therapeutics Receives Nasdaq Minimum Bid Price Notice
Negative
Jan 9, 2026
On January 7, 2026, Capstone Holding Corp. received notice from Nasdaq that its common stock had closed below the $1.00 minimum bid price requirement for 30 consecutive business days, placing the company out of compliance with Nasdaq’s conti...
Business Operations and StrategyM&A TransactionsPrivate Placements and FinancingShareholder Meetings
Capstone Therapeutics advances post-acquisition financing and governance arrangements
Positive
Dec 29, 2025
At its November 18, 2025 annual meeting, Capstone Holding Corp. shareholders unaffiliated with Nectarine Management LLC approved a letter agreement authorizing consent fees to Nectarine—owned by four Capstone directors and controlling the co...
Business Operations and StrategyM&A Transactions
Capstone Therapeutics Outlines 2026 Growth Strategy
Positive
Dec 15, 2025
On December 15, 2025, Capstone Holding Corp. released an investor presentation detailing its 2026 strategy, emphasizing its growth through acquisitions and organic expansion. The company has successfully integrated recent acquisitions, achieving a...
Business Operations and StrategyM&A Transactions
Capstone Completes Acquisition of Canadian Stone Industries
Positive
Dec 2, 2025
On December 1, 2025, Capstone Holding Corp. completed the acquisition of Canadian Stone Industries, a distributor with $15 million in annual revenue, which expands Capstone’s North American footprint and strengthens its brand portfolio. This...
Business Operations and StrategyPrivate Placements and Financing
Capstone Therapeutics Adjusts Convertible Note Conversion Price
Neutral
Nov 28, 2025
Capstone Holding Corp. has entered into a securities purchase agreement with an institutional investor, authorizing the issuance of senior secured convertible notes with an original principal amount of up to $10,909,885. On November 28, 2025, the ...
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
Capstone Therapeutics Approves Reincorporation to Nevada
Neutral
Nov 24, 2025
On November 18, 2025, Capstone Holding Corp. held its annual stockholders meeting where several key proposals were voted upon. The meeting, which had a quorum with 74.78% of votes represented, resulted in the election of two directors, the ratific...
Business Operations and StrategyFinancial DisclosuresM&A Transactions
Capstone Therapeutics Reports Record Q3 2025 Financial Results
Positive
Nov 17, 2025
Capstone Holding Corp. reported record financial results for the third quarter of 2025, with a 19% year-over-year increase in pro forma revenue and a 46% rise in adjusted EBITDA. The company announced two acquisitions expected to contribute $26 mi...
Business Operations and StrategyM&A Transactions
Capstone Completes Acquisition of Carolina Stone Holdings
Positive
Nov 7, 2025
On August 22, 2025, Capstone Holding Corp. completed its acquisition of Carolina Stone Holdings, LLC, and its subsidiary, Carolina Stone Distributors, LLC, from D22L, Inc. and other sellers. The transaction involved a cash payment of $2,625,000, s...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.